An association study between various monoamine transporter gene polymorphisms and treatment response to mirtazapine in major depression Background Genetic differences may contribute to the inter-individual differences in treatment response to antidepressants among patients suffering from major depression. This study investigated a possible association of various monoamine transporter genetic polymorphisms with treatment response to mirtazapine in major depressive patients in elderly.
Materials and methods
In this study, three genetic polymorphisms were selected: serotonin transporter 5-HTTLPR, serotonin transporter 5-HTT intron 2 VNTR, and norepinephrine transporter NET(G1287A). The patients with major depression diagnosed by DSM-IV were recruited to a 6-week naturalistic mirtazapine treatment study in Samsung Medical Center. Treatment response to mirtazapine was defined as ≥50% decrease in HAMD-17 scores at 6 weeks, and the genotypes in the patients were determined using the polymerase chain reaction.
Results
Our results showed that ss allele carriers were included more in responder group(ss allele in responder vs. non responder group; 69.4% vs. 40.0%). In addition, l-allele (sl/ll) carriers were included less in responder group(sl/ll allele in responder vs. non responder group; 30.6% vs. 
Conclusions
In conclusion, 5HTTLPR polymorphism may predict treatment response to mirtazapine in major depressive patients in elderly.
